Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
JP-1302 is an antagonist of α2-adrenergic receptors (α2-ARs) that is selective for α2C-ARs over α2A- and α2B-ARs (Kis = 28, 3,150, and 1,470 nM, respectively).1 It reduces immobility time in the forced swim test in mice when administered at doses of 1, 3, and 10 µmol/kg. JP-1302 (5 mg/kg) reverses phencyclidine-induced decreases in prepulse inhibition of the acoustic startle response in rats. It dose-dependently reduces haloperidol-induced bradykinesia and catalepsy in mice.2 JP-1302 (0.3 mg/kg) also increases systolic blood pressure in rats.3
WARNING This product is not for human or veterinary use.
1. Pharmacological characterization and CNS effects of a novel highly selective α2C-
2. Therapeutic potential of α2 adrenoceptor antagonism for antipsychotic-
3. Effect of selective blockade of α₂-